The Mounjaro dosing schedule described on the FDA label starts at 2.5 mg once weekly as a starter dose, then steps up by 2.5 mg every four weeks to a maximum of 15 mg once weekly, based on blood sugar control and tolerability. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes. This article is a clinical reference only; your prescriber individualizes the plan.
What Mounjaro Is
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. It was FDA-approved in May 2022 for adults with type 2 diabetes as an adjunct to diet and exercise. Tirzepatide is a once-weekly subcutaneous injection that activates two incretin receptors, GIP and GLP-1, which is why it is called a dual incretin agonist. The same molecule is also approved for chronic weight management under the brand name Zepbound.
The FDA Label Titration Framework
The Mounjaro label lays out a six-step titration schedule. Slow escalation is used to reduce gastrointestinal side effects such as nausea and vomiting. The table reflects the label and is for reference only; your prescriber decides the pace and endpoint based on your glucose response, side effects, and medical history.
| Step | Weekly Dose | Typical Duration Before Next Step | Role |
|---|---|---|---|
| 1 | 2.5 mg | 4 weeks | Starter dose; not for glucose control |
| 2 | 5 mg | At least 4 weeks | First maintenance dose |
| 3 | 7.5 mg | At least 4 weeks | Optional step-up |
| 4 | 10 mg | At least 4 weeks | Common maintenance dose |
| 5 | 12.5 mg | At least 4 weeks | Optional step-up |
| 6 | 15 mg | Ongoing | Maximum FDA-approved dose |
How the Injection Is Given
Mounjaro is supplied in pre-filled single-dose auto-injector pens. Each pen delivers one weekly dose. The injection is subcutaneous and typically given in the abdomen, thigh, or upper arm. Rotate sites each week to reduce irritation. Pens can be stored in the refrigerator until first use; once out of refrigeration, they should be used within 21 days and kept below 86 degrees Fahrenheit.
Pick a weekly dosing day that is convenient, for example every Sunday morning. The label allows the dosing day to be changed as long as the last two doses are at least 3 days apart.
Why Slow Titration Matters
Gastrointestinal side effects are the most common reason patients discontinue GLP-1 and dual incretin therapy. Starting at 2.5 mg and stepping up slowly allows the stomach and gut motility centers to adapt. Patients who jump too quickly often experience severe nausea, vomiting, and dehydration. Many clinicians extend each step beyond 4 weeks if side effects persist, rather than pushing escalation on a calendar.
Efficacy Data From the SURPASS Trials
The SURPASS clinical trial program, published across several New England Journal of Medicine papers, established tirzepatide’s efficacy. Headline results:
- A1C reductions of 1.8 to 2.1 percent at 5 mg, 2.0 to 2.4 percent at 10 mg, and 2.1 to 2.4 percent at 15 mg over 40 to 52 weeks
- Weight loss averaging 7.0 kg at 5 mg, 9.3 kg at 10 mg, and 11.2 kg at 15 mg
- Superiority over semaglutide 1 mg, insulin degludec, and insulin glargine in head-to-head comparisons
- Low rates of hypoglycemia when used without insulin or sulfonylureas
Missed Doses
The FDA label offers a specific rule for missed doses. If you remember within 4 days of your scheduled injection day, administer the missed dose and keep the original weekly schedule. If more than 4 days have passed, skip that week’s dose entirely and resume on your next scheduled day. Never inject two doses within 3 days of each other. If you have questions, call your prescriber or pharmacist.
Common Side Effects
The most common adverse events in SURPASS trials were gastrointestinal: nausea (reported by 12 to 22 percent depending on dose), diarrhea (12 to 17 percent), vomiting (5 to 9 percent), constipation (6 to 7 percent), and decreased appetite. Most symptoms were mild to moderate and resolved over the first 4 to 8 weeks. Injection site reactions were reported by about 3 percent of patients.
Serious Warnings on the Label
Mounjaro carries a boxed warning about thyroid C-cell tumors observed in rodents. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other serious warnings include pancreatitis, acute kidney injury (often related to dehydration from GI effects), hypoglycemia when combined with insulin, severe gastrointestinal disease, diabetic retinopathy complications, acute gallbladder disease, and hypersensitivity reactions.
How Mounjaro Fits Into Type 2 Diabetes Care
The ADA’s 2024 Standards of Care include tirzepatide as a high-efficacy option for glucose lowering and weight loss in adults with type 2 diabetes, especially when weight reduction is a meaningful goal. Metformin is still first line for most patients, but the ADA explicitly supports adding or switching to a GLP-1 or dual incretin when additional benefit is needed. For prediabetes, Mounjaro is not FDA-approved and is typically not first line. See our treatment guide, prediabetes overview, and A1C levels guide for more context.
Cost and Coverage
Mounjaro lists at roughly $1,070 per month at US retail. Most commercial insurance plans cover it for type 2 diabetes with prior authorization; Medicare Part D coverage varies by plan. Eli Lilly’s manufacturer savings card can reduce out-of-pocket cost to as low as $25 for eligible commercially insured patients. Off-label use for weight loss is generally not covered; Zepbound (the same molecule) is the approved brand for that indication.
The Bottom Line
The FDA-labeled Mounjaro dosing schedule starts at 2.5 mg weekly and steps up by 2.5 mg every 4 weeks to a maximum of 15 mg. The schedule is intentionally slow to reduce GI side effects, and many patients achieve their A1C and weight goals at intermediate doses like 5 or 10 mg without needing the maximum. This article is a reference framework only; your prescriber sets and adjusts the schedule that fits your health profile. This article is educational and is not medical advice.
